Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06830980 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

A NA study of HIV and Methamphetamine Use Disorders, sponsored by Gopalkumar Rakesh.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06830980 is a NA study of HIV and Methamphetamine Use Disorders that is actively recruiting participants, run by Gopalkumar Rakesh. The registered enrollment target is 30 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06830980, a NA study of HIV and Methamphetamine Use Disorders, is actively recruiting participants, sponsored by Gopalkumar Rakesh.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

Interventions

  • DEVICE continuous theta burst stimulation (cTBS)
  • DEVICE intermittent theta burst stimulation (iTBS)
  • DEVICE Sham TMS

Study Locations (1)

Kentucky

  • UK Department of Psychiatry - Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-11
Est. Completion 2026-12-31
Phase NA

Sponsor

Gopalkumar Rakesh

7 total trials

What the Registry Record Tells You About NCT06830980

The ClinicalTrials.gov registry entry for NCT06830980 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower). The listed sponsor is Gopalkumar Rakesh, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 3 interventions - of which continuous theta burst stimulation (cTBS) is the first listed.

NCT06830980 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT06830980 about?

NCT06830980 is a clinical study titled "Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH". The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

What is the current status of trial NCT06830980?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-11. Estimated completion is 2026-12-31.

What conditions does trial NCT06830980 study?

This clinical trial studies the following conditions: HIV, Methamphetamine Use Disorders.

What interventions are being tested in trial NCT06830980?

The interventions under investigation include: continuous theta burst stimulation (cTBS) (DEVICE), intermittent theta burst stimulation (iTBS) (DEVICE), Sham TMS (DEVICE).

Who is sponsoring clinical trial NCT06830980?

This trial is sponsored by Gopalkumar Rakesh, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06830980 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.